Michel Briejer is a managing partner at Thuja Capital which he joined early 2008. Prior to that, he held senior management positions both in the international pharmaceutical industry (e.g. Janssen Pharmaceutica (Belgium), Yamanouchi (currently Astellas Pharma)) as well as in the biotech industry (Crucell). Michel holds an MSc degree in Pharmacy (Utrecht University) and a PhD in Pharmacology (Wageningen University), as well as a post-doctoral degree in Pharmaceutical Medicine (Dip.Phar.Med., European Center for Pharmaceutical Sciences, Basle).
Erik Manting: after obtaining an MSc in Medical Biology and a PhD in Molecular Microbiology, Erik worked for a number of years in the field of immunology before making a career switch to banking in 2001. He spent the next 15 years in different commercial and management roles and his last five years in banking as Executive Director Corporate Finance at Kempen & Co, an investment bank with a focus on Life Sciences & Healthcare. Erik has been involved with Synerkine Pharma since 2017 and represents the founders in the supervisory board. He is currently also CEO at DCprime.
Michiel Palthe is a former partner of Veer Palthe Voûte, a successful asset management company in the Netherlands and that has been sold to Dresdner Bank in 1999. Before he was for 3 years in charge of the treasury of the Robeco Group. Michiel joined Citibank in 1979. Presently he is on the board and investment committee of Hoving&Partners in Geneva and chairman of the investment committee of a Gibraltar based family office. Also, he is an advisor to the Miller Turner Group and an active private investor.